ClinicalTrials.Veeva

Menu

A Study to Evaluate 608 in Patients with Non- Radiographic Axial Spondyloarthritis (nr-axSpA)

S

Sunshine Guojian Pharmaceutical

Status and phase

Enrolling
Phase 2

Conditions

Axial Spondyloarthritis

Treatments

Drug: 608
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT06222671
SSGJ-608-nr-axSpA-II-01

Details and patient eligibility

About

This study will evaluate the effect and safety of 608 in patients with nr-axSpA.

Full description

The purpose of this study is to demonstrate the clinical efficacy, safety and tolerability of 608 compared to placebo in patients with nr-axSpA.

Enrollment

180 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Female and male patients at least 18 years of age at the time of screening.
  2. Diagnosis of axial spondyloarthritis according to Ankylosing Spondylo Arthritis International Society (ASAS) axial spondyloarthritis criteria
  3. Objective signs of inflammation (magnetic resonance imaging (MRI) or abnormal C-reactive protein)
  4. Total back pain as measured by NRS ≥ 4 at baseline

Exclusion criteria

  1. Patients with other uncontrolled active inflammatory diseases.
  2. Clinical laboratory tests and other tests that reveal abnormalities with clinical significance
  3. Patients who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.
  4. History of cancer.
  5. Known or suspected history of immunosuppression.
  6. Known with allergic or intolerant to mometasone furoate spray or 608/placebo.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

180 participants in 3 patient groups, including a placebo group

608 Dose A
Experimental group
Description:
608 Dose A subcutaneous (SC) injection.
Treatment:
Drug: 608
Drug: 608
608 Dose B
Experimental group
Description:
608 Dose B subcutaneous (SC) injection.
Treatment:
Drug: 608
Drug: 608
Placebo
Placebo Comparator group
Description:
Placebo subcutaneous (SC) injection.
Treatment:
Drug: Placebo

Trial contacts and locations

6

Loading...

Central trial contact

Qinghong Zhou, BS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems